VCYTVeracyte, Inc.

$3B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+25.4% YoY

Gross Profit

$11M62.2% margin

Operating Income

-$7M-35.9% margin

Net Income

-$7M-39.7% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+12.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$88M

Total Liabilities

$41M

Stockholders' Equity

$48M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$15M	+25.4%
Gross Profit	$11M	$8M	+36.7%
Operating Income	-$7M	-$10M	+37.0%
Net Income	-$7M	-$11M	+35.1%

VCYT Q2 2017 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena